Moczygemba Awarded PhRMA Foundation Grant for Sleep Tracking Research

A woman wearing a necklace and smiling.
December 7, 2023
Professor of Health Outcomes Dr. Leticia Moczygemba was awarded a planning grant to test and validate wearable sleep tracking sensors to improve health outcomes for people experiencing homelessness (PEH).

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

Improving Health Outcomes for People Experiencing Homelessness is Focus of New Study

Five people holding cell phones and wearing masks.
April 30, 2021
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.

New Delivery Method Could Make Niclosamide an Effective Antiviral to Treat COVID-19

Two men in suits smiling.
April 6, 2020
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.

Williams named Inventor of the Year

Bill Williams Profile Pic
November 3, 2017
Bill Williams was named the 2017 Inventor of the Year by the university’s Office of Technology Commercialization.